Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Immune Therapeutics, Inc. (OTC: IMUN).

Full DD Report for IMUN

You must become a subscriber to view this report.


Recent News from (OTC: IMUN)

Immune Therapeutics, Inc. Files New Drug Application for Lodonol(TM) in Kenya to Target HIV Epidemic
ORLANDO, Fla., April 26, 2018 (GLOBE NEWSWIRE) -- via OTC PR WIRE-- Immune Therapeutics, Inc. (OTCQB:IMUN) ("Immune" “IMUN” or the "Company"), a clinical late stage biopharmaceutical company focused on the development of therapies for the treatment of autoimmune diseases, infl...
Source: GlobeNewswire
Date: April, 26 2018 08:30
Immune Therapeutics on go with late-stage study of IRT-103 in Crohn's
Immune Therapeutics ( OTCQB:IMUN -7.9% ) plans to file an application with the FDA seeking sign-off on a Phase 3 clinical trial assessing IRT-103, branded as Lodonal, for the treatment of patients at least 12 years old with moderate-to-severe Crohn's disease. The study should launch in H...
Source: SeekingAlpha
Date: March, 26 2018 12:08
Immune Therapeutics, Inc. Received Minutes From FDA Meeting for Lodonal(TM) for the Treatment for Crohn's Disease
ORLANDO, Fla., March 26, 2018 (GLOBE NEWSWIRE) -- via OTC PR WIRE-- Immune Therapeutics, Inc. (OTCQB:IMUN) ("Immune" "IMUN" or the "Company"), a clinical late stage biopharmaceutical company focused on the development of two immunomodulating therapies (IRT-103 "Lodonal™" and IRT-101"...
Source: GlobeNewswire
Date: March, 26 2018 09:35
Immune Therapeutics, Inc. Announces First Sales & Shipment of Lodonal; Receives Trademark and Patent Approval From Federal Republic of Nigeria
ORLANDO, Fla., Feb. 20, 2018 (GLOBE NEWSWIRE) -- via OTC PR WIRE-- Immune Therapeutics, Inc. (OTCQB:IMUN) ("Immune" “IMUN” or the "Company"), a clinical late stage biopharmaceutical company focused on the development of two immunomodulating therapies (IRT-103 “Lodonal&#...
Source: GlobeNewswire
Date: February, 20 2018 08:30
Immune Therapeutics, Inc. Announces First Sales & Shipment of Lodonal; Receives Trademark and Patent Approval From Federal Republic of Nigeria
Immune Therapeutics, Inc. Announces First Sales & Shipment of Lodonal; Receives Trademark and Patent Approval From Federal Republic of Nigeria
Source: OTC Markets
Date: February, 20 2018 00:00
Immune Therapeutics, Inc. Shareholder Update Letter
ORLANDO, Fla. , Nov. 30, 2017 /PRNewswire/ --  Immune Therapeutics, Inc. (OTCQB: IMUN), a biopharmaceutical company engaged in the development and commercialization of specialty pharmaceutical and biotechnology products to alleviate human suffering in HIV/AIDS, cancer, pain, opportu...
Source: PR Newswire
Date: November, 30 2017 09:58
Immune Therapeutics, Inc. Announces Exclusive Agreement for Sale of Lodonal in Kenya Valued at Over $31 Million
ORLANDO, Fla., Sept. 06, 2017 (GLOBE NEWSWIRE) -- Immune Therapeutics, Inc. (OTCQB:IMUN), a specialty pharmaceutical company focused on developing and commercializing Lodonal™, its patented, affordable, non-toxic therapy for the management of cancer, HIV, autoimmune diseases and ...
Source: GlobeNewswire
Date: September, 06 2017 09:12
Immune Therapeutics, Inc. Announces Exclusive Agreement For Sale Of Lodonal In Kenya Valued At Over $31 Million
ORLANDO, Fla. , Sept. 6, 2017 /PRNewswire/ --  Immune Therapeutics, Inc. (OTCQB: IMUN), a specialty pharmaceutical company focused on developing and commercializing Lodonal™, its patented, affordable, non-toxic therapy for the management of cancer, HIV, autoimmune diseases an...
Source: PR Newswire
Date: September, 06 2017 08:05
Immune Therapeutics, Inc. Appoints John H. Abeles, M.D. as Chairman and CEO of Company's Subsidiary, Cytocom, Inc. and as Senior Adviser to Immune Therapeutics, Inc.
ORLANDO, Fla., Aug. 23, 2017 (GLOBE NEWSWIRE) -- Immune Therapeutics, Inc. (OTCQB:IMUN) today announced that it has appointed John H. Abeles, M.D.  as Chairman and CEO of its subsidiary, Cytocom, Inc. , a specialty clinical-stage biopharmaceutical company that develops therapies fo...
Source: GlobeNewswire
Date: August, 23 2017 09:04
Immune Therapeutics to Present at the 7th Annual LD Micro Invitational
LOS ANGELES, CA / ACCESSWIRE / June 5, 2017 / Immune Therapeutics, Inc. (OTCQB: IMUN), a specialty pharmaceutical company focused on developing and commercializing our novel patented, affordable, non-toxic therapy for the management of cancer, HIV, autoimmune diseases, and other inflammatory...
Source: ACCESSWIRE IA
Date: June, 05 2017 08:45

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-08-210.01970.01970.01970.01972,000
2018-08-200.01710.01970.01990.0171422,800
2018-08-170.01990.01720.01990.0164118,851
2018-08-160.01690.017120.01780.0153777,322
2018-08-150.020.01840.020.0169560,700

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-2062,451422,80014.7708Cover
2018-08-1759,502118,85150.0644Short
2018-08-16236,565873,32127.0880Cover
2018-08-15166,000570,70029.0871Cover
2018-08-1495,993347,32627.6377Cover

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on IMUN.


About Immune Therapeutics, Inc. (OTC: IMUN)

Logo for Immune Therapeutics, Inc. (OTC: IMUN)

Immune Therapeutics, Inc. is a biotechnology company developing and seeking to commercialize patented therapies in emerging nations that combat chronic, life threatening diseases by stimulating or rebalancing the immune system. Our technology platform is based on two interrelated cytokine drug therapies Low Dose Naltrexone LDN and Methionine Enkephalin MENK which work by triggering opioid receptors on immune cells to activate various cells of the immune system.

 

 

 

Current Management

  • Noreen Griffin / CEO
  • Rudy Williams / COO
    • Rudy Williams is the former president of International Engineering Services, Inc. IESINC one of the country s largest minority owned engineering service company in the early and late seventies, . He sold IES in . In the mideighties, Mr. Williams identified the need for a government affairs firm dedicated to small business issues and formed The Phoenix Group. The Phoenix Group is a public affairs company that specializes in federal government, legislative representation, and internal relations. Mr. Williams also created Direct Pharmacy Service, Inc. DPSI in the early nineties with his partner James Hill now deceased . DPSI became the largest Mail Order Pharmacy, operating from their facilities in the Southern sector of the U.S. The interface with government regulations, rules extended to DPSI to become a Pharmacy Benefit Management Company which intensified relations with federal government health care regulations. Mr. Williams has a BS/MS degree in Electrical Engineering attended Tuskegee Institute, Arizona State University and Massachusetts Institute of Technology MIT .
  • Peter Aronstam / CFO
  • Dr. Fengping Shan / Chief Scientific Officer
  • Gina Austin / General Counsel
  • Nicholas Plotnikoff / NonExecutive Chairman
  • Paul Akin /
  • Noreen Griffin /
  • Clifford A. Selsky /
  • Edward Teraskiewicz /

Current Share Structure

  • Market Cap: $11,581,633 - 03/09/2018
  • Authorized: 500,000,000 - 02/28/2018
  • Issue and Outstanding: 387,345,599 - 02/28/2018
  • Float: 7,986,000 - 12/11/2015

 


Recent Filings from (OTC: IMUN)

Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 15 2018
Statement of beneficial ownership of common stock by certain persons
Filing Type: SC 13GFiling Source: edgar
Filing Date: May, 15 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 27 2018
Annual statement of changes in beneficial ownership of securities
Filing Type: 5Filing Source: edgar
Filing Date: April, 02 2018
Annual statement of changes in beneficial ownership of securities
Filing Type: 5Filing Source: edgar
Filing Date: April, 02 2018
Annual statement of changes in beneficial ownership of securities
Filing Type: 5Filing Source: edgar
Filing Date: April, 02 2018
Annual statement of changes in beneficial ownership of securities
Filing Type: 5Filing Source: edgar
Filing Date: April, 02 2018
Annual statement of changes in beneficial ownership of securities
Filing Type: 5Filing Source: edgar
Filing Date: April, 02 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: April, 02 2018
Annual statement of changes in beneficial ownership of securities
Filing Type: 5Filing Source: edgar
Filing Date: April, 02 2018

 

 


Daily Technical Chart for (OTC: IMUN)

Daily Technical Chart for (OTC: IMUN)


Stay tuned for daily updates and more on (OTC: IMUN)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: IMUN)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in IMUN is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of IMUN and does not buy, sell, or trade any shares of IMUN. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/